Introduction
Protein tyrosine phosphatases (PTPases) are a family of proteins that perform the enzymatic role to remove phosphate groups from phosphotyrosine residues of specific targets inside cells. PTPases regulate important cellular processes like gene expression, cell activation and proliferation, differentiation, development, transport and locomotion, since they counterbalance the growth-promoting effects of protein tyrosine kinases (PTKs), which catalyse the phosphorylation of tyrosine residues (Shock et al., 1995) . Therefore, alterations in PTPs activity might affect cell growth, neoplastic processes and transformation (Gaits et al., 1995) . Addition of the PTPase-inhibitor vanadate to cells in culture leads to increased amounts of phosphotyrosinecontaining proteins and cellular transformation (Klarlund, 1985) . Therefore, a delicate balance between PTK and PTPase action is essential for normal functioning of cells.
PTPg is a member of the receptor-like family of tyrosine-specific phosphatases originally cloned from human brainstem and placental cDNA libraries using probes derived from the intracellular domain of CD45 (Kaplan et al., 1990) or Drosophila PTPase cDNA clone, DPTP12 (Krueger et al., 1990) , respectively. The structure of the receptor-like PTPs (RPTPs) includes an extracellular, a transmembrane, and one or two tandemly repeated catalytic domains. This structure implies a ligand-binding capability that may modulate enzymatic activity. However, the putative ligands for most of the PTPs with receptor-like structures are yet to be identified. Receptor-like PTPg has a carbonic anhydrase-homologous amino terminus followed by a fibronectin type three domain, a cysteine-free domain, a transmembrane domain and two intracellular PTPase catalytic domains (Krueger and Saito, 1992; Barnea et al., 1993; Levy et al., 1993) . According to mRNA analysis Barnea et al., 1993) , PTPg is a broadly expressed enzyme that exists in many tissues, including human lung, stomach, esophagus, colon, liver, spleen and kidney (Tsukamoto et al., 1992) . Based on the chromosomal location of the PTPg gene (3p14.2) and studies showing loss of heterozygosity of the gene in kidney tumors (Lubinski et al., 1994) , PTPg has been implicated as a candidate tumor suppressor gene. More recently, PTPg expression levels were shown to be reduced in ovarian and lung tumors (van Niekerk and Poels, 1999) . Our previous results showed lower PTPg mRNA expression levels in diethylstilbestrol-induced kidney tumors in hamsters than in normal hamster kidney (Lin et al., 1994) . Also, we have shown that, in ACI rats, PTPg is localized to the mammary epithelium and that zeranol (Z), a nonsteroidal agent with estrogenic activity that is used as a growth promoter in the US beef and veal industries, can suppress PTPg mRNA levels in mammary glands . Furthermore, we have reported that PTPg is expressed in normal and malignant human breast epithelium, and PTPg mRNA levels can be suppressed by estrogens through an estrogen receptor-mediated mechanism (Zheng et al., 2000) . More recently, our results showed that PTPg mRNA expression was lower in cancerous than in normal breast tissues; both 17b-estradiol (E 2 ) and Z suppressed PTPg mRNA levels in both cultured normal breast tissues and cultured breast cells isolated from normal breast tissues. In whole breast tissues, PTPg was immunolocalized to the epithelium and treatment with E 2 or Z diminished PTPg staining, which indicated reductions in PTPg at the protein level (Liu et al., 2002) . These findings suggest that PTPg is a potential estrogenregulated tumor suppressor gene in human breast cancer that may play an important role in neoplastic processes of human breast epithelium, and indicate an intriguing relationship among cancer, estrogen and PTPg.
The aim of the present study was to examine the effect of PTPg on the growth of human breast cancer and compare the estrogenic responses of human breast cells with different expression levels of PTPg. MCF-7 breast cancer cells were used as a model and we stably transfected a plasmid containing the whole PTPg coding sequence or containing a small portion of PTPg coding sequence in the antisense orientation into human MCF-7 breast carcinoma cells. PTPg-overexpressing MCF-7 cells normally show the characteristics with slowgrowing and lower colony efficiency on soft agar, and show antiestrogenic effects on human breast cell proliferation.
Results

Comparison of PTPg expression in stably transfected MCF-7 cells
MCF-7 cells were transfected with pCR s 3.1 vector (M7-pCR s 3.1-800 (s)), full-length PTPg (M7-PTPg-800 (s)), PTPg antisense construct (M7-A24-800 (s)) or PTPg sense construct (M7-B19-800 (s)). Based on the doseresponse curve of each transfected cell line to G-418, it was determined that 800 mg/ml was the optimal dose of G-418 for the single colony selection in every transfected cell line. We have selected five single clones from mocktransfected MCF-7 cells (M7-pCR s 3.1-800 (s)), 19 single clones from PTPg-transfected MCF-7 cells (M7-PTPg-800 (s)), 17 single clones from antisense PTPgtransfected MCF-7 cells (M7-A24-800 (s)) and 11 single clones from sense PTPg-transfected MCF-7 cells (M7-B19-800 (s)). To identify the successfully and ideally transfected single colonies, RT-PCR with a set of specific primers was used for each group of transfection (Figure 1) . The results showed that 13 out of 19 clones from M7-PTPg-800 (s) expressed exogenous PTPg mRNA, and all of the single clones from M7-pCR s 3.1-800, M7-A24-800 and M7-B19-800 were successful. Furthermore, PTPg mRNA expression was compared among those successfully transfected cell lines. Our results showed that M7-PTPg-800 (s) had higher PTPg mRNA expression than any of wild-type MCF-7, M7-pCR s 3.1-800, M7-A24-800 and M7-B19-800 cell lines. M7-A24-800 had lower PTPg mRNA expression than any of wild-type MCF-7, M7-pCR s 3.1-800, M7-PTPg-800 and M7-B19-800 cell lines (Figure 2) . Also, the results from immunohistochemical staining showed that the PTPg staining was weak and very similar to that of wild-type MCF-7 cell (Figure 3a) , M7-pCR s 3.1-800 (s) (Figure 3b ) and M7-B19-800 (s) (Figure 3c) . Furthermore, the degree of staining was observably increased in M7-PTPg-800 (s) (Figure 3d ) when compared to others; however, the degree of staining was almost diminished in M7-A24-800 (s) (Figure 3e ) when compared to others. Thus, these results indicate that PTPg is overexpressed in M7-PTPg-800 (s) and is greatly reduced in M7-A24-800 (s) compared to other cells. These results are consistent with those presented in Figure 2 .
Effects of PTPg on the proliferation of MCF-7 cells
To check whether PTPg level has an antimitogenic effect on MCF-7 cells, a proliferation study was performed by means of doubling time assay. Wild-type MCF-7 cells, M7-pCR s 3.1-800 (s) and M7-B19-800 (s) had the mean cell population doubling time of 24.072, 24.373 and 23.871 h, respectively, but it was increased to 40.073 h for M7-PTPg-800 (s) (B60% increase) and it was decreased to 16.471 h for M7-A24-800 (s) (B34% decrease) (Figure 4) . These results suggested that PTPg 5 viable cells from wild-type MCF-7 cells and each single colony were plated in one well of six-well plates with 5 ml of culture medium separately and cultured to B85% confluence, total RNA was isolated for each group, and RT-PCR was performed. Ethidium bromide-stained PCR products separated in a 1.5% agarose gel. 36B4 was used as internal standard. Primer 305 is located in BGH reverse priming site in pCR s 3.1 vector; primer 333 is located in the sense strand of full-length PTPg cDNA insert; primer 83 is located in T7 promoter/ priming site in pCR 
Effects of PTPg on anchorage-independent growth of MCF-7 cells
The acquisition of anchorage-independent growth is generally considered to be one of the in vitro properties associated with the malignancy of cells. The transfected cells were examined for their ability to grow in soft agar. First, we checked the optimal number of cells for the colony formation in six-well plates seeded with different number of wild-type MCF-7 cells, M7-pCR s 3.1-800 (s) or M7-PTPg-800 (s). The results showed that the colony number in soft agar was increased while the seeded cell number was increased for each cell type, M7-PTPg-800 (s) formed much less and smaller colonies in soft agar than wild-type MCF-7 cells and M7-pCR s 3.1-800 (s) in the same seeded cell number group (data not shown). Also, we determined that 8000 cells/well was the optimal MCF-7 cell number for the future soft agar assay in our experiment. Furthermore, we found that M7-PTPg-800 (s) formed less and smaller colonies in soft agar than wild-type MCF-7 cells and M7-pCR s 3.1-800 (s), but M7-A24-800 (s) formed more and much larger colonies in soft agar than wild-type MCF-7 cells, M7-pCR s 3.1-800 (s) and M7-B19-800 (s) ( Figure 5 ). These in vitro data indicated that PTPg is able to inhibit proliferation and anchorage-independent growth of breast cancer cells.
Effects of PTPg on estrogenic activities of E 2 and Z on MCF-7 cell proliferation
As we have known, E 2 is a potent mitogen for human breast cancers. Z is a nonsteroidal anabolic growth promoter with estrogenic activities. Our previous results showed that both Z and E 2 could induce normal human breast epithelial cell transformation and stimulate human breast cell proliferation in a dose-dependent manner, and suggested that PTPg is a potential estrogen-regulated tumor suppressor gene in human breast cancer that may play an important role in neoplastic processes of human breast epithelium, which indicates an intriguing relationship among cancer, estrogen and PTPg. The established stably transfected cell lines with different PTPg expression levels were used to examine whether PTPg has any antiestrogenic activities on MCF-7 cell proliferation. Our results showed that both Z and E 2 could stimulate the cell proliferation of wild-type MCF-7, M7-pCR s 3.1-800 (s), M7-PTPg-800 (s), M7-B19-800 (s) and M7-A24-800 (s) in a dose-dependent manner, and the potency of Z and E 2 are very similar on the stimulation of cell proliferation ( Figure 6 ). Most interestingly, the degree of Z's or E 2 's stimulation on M7-PTPg-800 (s) cell proliferation A total of 1.5 Â 10 5 viable cells from wild-type MCF-7 cells, one of single colonies from mock transfected MCF-7 cells, and three of single colonies from M7-PTPg-800 (s), M7-B19-800 (s) or M7-A24-800 (s) were plated in one well of six-well plates with 5 ml of culture medium separately and cultured to B85% confluence, total RNA was isolated for each group, and RT-PCR was performed. Top: Ethidium bromide-stained PCR products separated in a 1.5% agarose gel. Cells were not treated and total RNA was isolated from each cell type separately. 36B4 was used as internal standard. Bottom: The mRNA ratios of PTPg to 36B4 as measured by densitometry Figure 3 Immunohistochemical staining for PTPg in transfected MCF-7 cells. Cells were cultured on 24 Â 30 mm cell culture cover slips overnight and washed in PBS for three times. After À101C methanol fixation for 5 min and air-dry, cells were stained for PTPg by using VECTASTAIN s Universal Quick Kit and DAB Substrate Kit. Brown staining represents PTPg immunoreactivity; blue staining represents nuclei: (a) Wild-type MCF-7 cells; (b) M7-pCR Figure 6d ) is much less than that on the cell proliferation of wild-type MCF-7, M7-pCR s 3.1-800 (s) or M7-B19-800 (s) cell proliferation ( Figure 6a-c) ; however, the degree of Z's or E 2 's stimulation on M7-A24-800 (s) cell proliferation (Figure 6e ) is much greater than that on the cell proliferation of wild-type MCF-7, M7-pCR s 3.1-800 (s) or M7-B19-800 (s) cell proliferation (Figure 6a-c) . These results indicated that PTPg overexpression could reduce the estrogenic responses of MCF-7 cell proliferation to E 2 and Z and has antiestrogenic activities on human breast cancer cells.
Discussion
Transmembrane receptor tyrosine phosphatases represent a growing family of enzymes, the structural features of which suggest a role in the control of cellular phosphotyrosine balance. However, the biological significance of PTPg is only poorly understood. PTPg has been considered as a candidate tumor suppressor gene due to the location of its gene on human chromosome 3p14.2, in a region found to be frequently deleted in Figure 4 Effects of PTPg on the proliferation of MCF-7 cells. In total, 5000 cells/well were seeded in 24-well plates and cells were grown for 3 days and counted every 8 h. Experiments were performed in four replicate wells, and each experiment was repeated twice. Cell doubling (CD) was calculated by using the formula: ln (N j ÀN i )/ln 2, where N j or N i is the cell numbers at different time point T j or T i (T j 4T i ) in the growth log phase of the cells. DT was consequently obtained by dividing the time interval (T j 4T i ) by CD Figure 5 Effects of PTPg on anchorage-independent growth of MCF-7 cells. (a) Colony formation of different MCF-7 cell types in soft agar. Cells were cultured in six-well plates first covered with an agar layer (phenol red-free high-calcium DMEM/F12 with 0.5% agar and 10% FBS). The middle layer contained 8000 cells/well in phenol red-free DMEM/F12 with 0.35% agar and 10% FBS. The top layer, consisting of medium, was added to prevent drying of the agar in the plates. The plates were incubated for 21 days, after which the plates were stained in 0.5 ml of 0.005% crystal violet for 41 h and the cultures were inspected and photographed. (b) Comparison of CE among different MCF-7 cell types. CE was determined by a count of the number of colonies greater than 15 mm in diameter, which was calculated as the average of colonies counted at Â 50 magnification in five individual fields by using BioQuant NOVA software. Bar: 50 mm Figure 6 Effects of PTPg on estrogenic activities of E 2 and Z on MCF-7 cell proliferation. In total, 2 Â 10 4 cells were cultured in each well of 24-well plates and treated with the E 2 or Z at 0, 7.5, 15, 30, 60 or 120 nM in phenol red-free high-calcium DMEM/F12 supplemented with DCC-stripped FBS (5%) for 24 h. Cell proliferation rate was quantified by using CellTiter 96t AQueous assay and optical density was read at 490 nm (OD 490 nm ) in 96-well plates by an ELISA plate reader. Each point presented the mean7s.d. of four replicate culture wells. Asterisk represents the significant difference from the control group. A probability (P) of less than 0.05 was considered to be statistically significant (Po0.05). Effects of PTPc on the growth of MCF-7 cells S Liu et al certain types of renal and lung carcinoma Barnea et al., 1993) . Our previous results suggest that PTPg is a potential estrogenregulated tumor suppressor gene in human breast cancer that may play an important role in breast tumorigenesis (Lin et al., 1994; Kulp et al., 2000; Zheng et al., 2000; Liu et al., 2002) . But, the function of PTPg in human breast cancer is still not clear.
To examine the effect of PTPg on the growth properties of human breast cancer cells in vitro and provide a biochemical background for understanding PTPg function, we transfected PTPg-expressing vector with a variant full-length PTPg cDNA lacking the intracellular juxtamembrane exon of the reported PTPg cDNA, which is expressed as the dominant isoform in most tissues (Sorio et al., 1995) , or PTPg antisense construct into MCF-7 cells. It is clear from the data shown in Figure 4 that the relationship of link for the PTPg and longer doubling time as well as less colony formation is intimately related. When the breast cancer cells have higher levels of PTPg mRNA or its protein, the proliferative ability of breast cancer cells will be greatly suppressed or blocked.
The results from doubling time assay and soft agar assay showed that MCF-7 cells overexpressing PTPg has the characteristics with slow-growing and lower colony efficiency on soft agar. Furthermore, the results from the cell proliferation assay showed that MCF-7 cells overexpressing PTPg can antagonize estrogenic effects of E 2 and Z on MCF-7 cell proliferation, which indicates PTPg has antiestrogenic effects on human breast cancer.
In combination with our previous results which showed that PTPg mRNA expression was significantly lower in cancerous than in normal breast tissues and both E 2 and Z suppressed PTPg mRNA levels in cultured normal breast tissues and cultured normal breast cells isolated from the tissues, all these experimental data support our suggested concept that PTPg is a potential estrogen-regulated breast cancer suppressor gene. This molecular biomarker will be a powerful tool for investigating the estrogen and/or nonsteroidal estrogenic agents in controlling the etiological process of tumorigenesis in human breast and rodent mammary. It was claimed that the reduction of PTPg expression in human breast cancer is unlikely to be due to genetic events; therefore, epigenetic mechanisms (such as methylation) might be responsible. Several genes have been demonstrated to be hypermethylated in breast carcinomas, including HIN-1, p16, E-cadherin, BRCA1, estrogen receptor, glutathione S-transferase P1 (GSTP1), mammary-derived growth inhibitor (MDGI), HoxA5 and 14-3-3s (Krop et al., 2001) . To identify the mechanisms of PTPg reduction in human breast cancer and PTPg downregulation by E 2 and Z, human PTPg promoter region analysis and investigation of hypermethylation in PTPg need to be conducted in the future.
Our data are the first evidence to demonstrate that the PTPg does exert its suppressor capability to inhibit or slow down the proliferation of MCF-7 cells and does have the antiestrogenic activities on human breast cancers exposed to E 2 or Z. Although the in vivo function of PTPg is unknown, its reduced expression in breast carcinomas and decreased colony formation following its overexpression suggest a tumor suppressor role. If similar results can be reproduced in athymic mouse testing model, then the presence of this potential cancer suppressor gene and its protein will significantly prolong the survivability of human breast cancer patients by inhibiting or slow down the proliferative ability of human breast cancer cells. The signaling pathway with PTPg involvement may provide a new target for cancer prevention and treatment. In the future, PTPg might be able to be applied in clinical trials for cancer prevention and cancer therapy.
Materials and methods
Cell culture
The human breast cancer cell line MCF-7 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were maintained in a mixture of Dulbecco's modified Eagle's medium and Ham's F12 medium (1 : 1) (DMEM/F12) without phenol red (Sigma Chemical Co., St Louis, MO, USA) supplemented with 5% fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, GA, USA) and antibiotic-antimycotic (100 U/ml penicillin G sodium, 100 mg/ ml streptomycin sulfate and 0.25 mg/ml amphotericin B) (GibcoBRL, Bethesda, MD, USA) and were plated separately in 75-cm 2 culture flasks in a humidified incubator (5% CO 2 : 95% air, 371C). The media were changed every 2 days. When the cells grew to about 85% confluence, cells were washed twice with calcium-and magnesium-free phosphate-buffered saline (PBS, pH 7.3), and then trypsinized with 0.5% trypsin-5.3 mM EDTA (GibcoBRL) in PBS for 10 min at 371C. The trypsinization was stopped by addition of culture medium with 5% FBS. After centrifugation, the dissociated cells were resuspended in the same medium and subcultured into 75-cm 2 culture flasks at a ratio of 1 : 5 flasks.
Transfection
The expression vector pCR s 3.1 (Invitrogen, Carlsbad, CA, USA), containing a human full-length PTPg cDNA (5.3 kb) in an EcoRI site or a partial PTPg cDNA fragment (756 bp amplified using the following primer set: 5 0 -CGTCAC-CAGTCTCCTATTGA-3 0 and 5 0 -GTCTGTCATGTCGTG-GTTCC-3 0 ) cloned in pCR s 3.1 vector. Clones containing the construct in the sense or antisense orientation were selected and used for transfection (Sorio et al., 1995 (Sorio et al., , 1997 . As a control, we used an empty pCR s 3.1 vector (mock). Plasmids (10 mg) were transfected into MCF-7 cells by using Superfect (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. At 48 h after transfection, the cells were transferred to selection medium containing different doses (0, 100, 200, 400, 600, 800, 1000 mg/ml) of G-418 (Geneticin) (Invitrogen, Carlsbad, CA, USA) for 6 days to determine the optimal dose of G-418 for the selection. Finally, surviving single colonies from four to five dishes with selection medium containing 800 mg/ml of G-418 were picked from each stably transfected group for future culture and cells were treated with 400 mg/ml of G-418 in the culture medium every two to three passages to maintain the homogeneity of the cells.
RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)
A total of 1.5 Â 10 5 viable cells from each single colony were plated in one well of six-well plates with 5 ml of culture medium and cultured to B85% confluency. Total RNA was isolated in 1 ml of TRIZOL s Reagent (GibcoBRL) according to the manufacturer's instructions. RT-PCR was performed in a gradient mastercycler (Eppendorf s ). PCR conditions were optimized for MgCl 2 concentration, annealing temperature and cycle number for the amplification of each of the PCR products. Under optimal conditions, the amounts of PCR products generated fell within the linear portion of the PCR amplification curve between 26 and 39 amplification cycles. Briefly, 1 mg of total RNA from cultured cells or tissues was reverse transcribed with 200 U M-MLV Reverse Transcriptase (GibcoBRL) at 421C for 1 h in the presence of 5 mM each of dATP, dCTP, dGTP and dTTP, 4 ml 5 Â first-strand buffer (GibcoBRL), 0.01 M DDT, 1 U RNA Guard RNase inhibitor (Pharmacia Biotech, Uppsala, Sweden), and 2.5 mM random hexamers in a total volume of 20 ml. The reaction was terminated by heating to 951C for 3 min. The newly synthesized cDNAs were used as templates for PCR after adjusting reagent concentrations to 3.5 mM MgCl 2 , 2.5 ml 10 Â PCR Buffer (GibcoBRL), 1 U Platinum s Taq DNA polymerase (GibcoBRL), and 0.24 mM primers. The reactant was incubated at 951C for 5 min. Then, 30 cycles of amplification were performed with each cycle consisting of denaturation at 951C for 1 min, annealing at 631C for 1 min, and extension at 721C for 1 min. The primer sequences generating 990 bp PCR products for full-length PTPg construct were 5 0 -GTA TGG AGC AGT TTC AGC-3 0 (sense at PTPg exon 29) and 5 0 -TAG AAG GCA CAG TCG AGG-3 0 (antisense at pCR s 3.1 reverse priming site). The primer sequences generating 583 bp PCR products for antisense PTPg construct were 5 0 -TAA TAC GAC TCA CTA TAG GG-3 0 (sense at T7 promoter priming site in pCR 0 (antisense at PTPg exon 11). The primer sequences generating 563 bp PCR products for 36B4 were 5 0 -AAA CTG CTG CCT CAT ATC CG-3 0 (sense at 306-325) and 5 0 -TTG ATG ATA GAA TGG GGT ACT GAT G-3 0 (antisense at 868-848). The final PCR products (10 ml) mixed with 1 ml of 10 Â loading buffer were separated on a 1.5% agarose gel containing ethidium bromide. The specific bands were quantified by ImageQuaNT software (Molecular Dynamics, Sunnyvale, CA, USA). The results are presented as the ratio of each PCR product to 36B4. 36B4 is a cDNA clone for human acidic ribosomal phosphoprotein PO (Masiakowski et al., 1982) , for which mRNA levels have been shown to be unmodified by estradiol treatment (Laborda, 1991) .
Immunohistochemical staining
Wild-type MCF-7 cells (MCF-7), mock-transfected MCF-7 cells (M7-pCR s 3.1-800 (s)), PTPg-overexpressed MCF-7 cells (M7-PTPg-800 (s)), antisense PTPg-transfected MCF-7 cells (M7-A24-800 (s)) and sense PTPg-transfected MCF-7 cells (M7-B19-800 (s)) were cultured on 24 Â 30 mm cell culture cover slips (Cat. No: 150067, Nalge Nunc Int., Naperville, IL, USA) and washed in PBS for three times. After À101C methanol fixation for 5 min and air-dry, cells were stained for PTPg by using VECTASTAIN s Universal Quick Kit and DAB Substrate Kit (Cat. No. PK-8800, Cat. No. SK-4100, Vector Laboratories, Inc., Burlingame, CA, USA) according to the manufacturer's instructions. The primary antibody was an affinity-purified rabbit polyclonal antibody raised against a self-designed in-house synthetic peptide (N-SEDGERE-HEEDGEKD-C) corresponding to amino acids 588-602 mapping in the extracellular domain of the PTPg precursor of human origin and was produced by Sigma s Genosys (The Woodlands, TX, USA). An optimal primary antibody dilution of 1 : 100 was determined by titration in this system, and omission of primary antibody served as a negative control.
Doubling time assay
Wild-type MCF-7 cells, M7-pCR s 3.1-800 (s), M7-PTPg-800 (s), M7-A24-800 (s) and M7-B19-800 (s) were plated separately at a density of 0.5 Â 10 4 cells/well in 24-well plates in a volume of 1 ml/well. After cells are attached to the wells, the medium was replaced with 2 ml of fresh DMEM/F12 with 5% FBS. At the same time (time 0 h), a group of cells were counted. Cells were grown for 3 days and counted every 8 h. Adherent cells were detached by rapid trypsinization. An adequate volume of medium containing trypan blue was added. Then cells were counted by using a hemacytometer. Experiments were performed in four replicate wells, and each experiment was repeated twice. Based on the counted cell numbers at different time points, a cell proliferation curve was generated. Cell doubling (CD) was calculated by using the formula: ln (N j ÀN i )/ln 2, where N j or N i is the cell numbers at different time point T j or T i (T j 4T i ) in the growth log phase of the cells. Doubling time (DT) was consequently obtained by dividing the time interval (T j 4T i ) by CD (Poliseno et al., 2002) .
Soft agar assay for colony formation
Cells were cultured in six-well plates first covered with an agar layer (phenol red-free DMEM/F12 with 0.5% agar and 10% FBS. The middle layer contained different number of cells (2000, 4000, 8000 or 16 000 cells) in phenol red-free DMEM/ F12 with 0.35% agar and 10% FBS. The top layer, consisting of medium, was added to prevent drying of the agar in the plates. The plates were incubated for 21 days, after which the plates were stained in 0.5 ml of 0.005% crystal violet for 41 h and the cultures were inspected and photographed. Colony efficiency (CE) was determined by a count of the number of colonies greater than 15 mm in diameter, which was calculated as the average of colonies counted at Â 50 magnification in five individual fields by using BioQuant NOVA software.
Nonradioactive cell proliferation assay
A total of 2 Â 10 4 cells (Wild type MCF-7 cells, M7-pCR s 3.1-800 (s), M7-PTPg-800 (s), M7-A24-800 (s) or M7-B19-800 (s)) were seeded and cultured in each well of 24-well plates in phenol red-free high-calcium DMEM/F12 supplemented with 5% FBS overnight. The medium was switch to phenol red-free high-calcium DMEM/F12 supplemented with Dextran-coated charcoal (DCC) (Dextran T-70, Pharmacia; activated charcoal, Sigma)-stripped FBS (5%). After 24 h, cells were treated with the E 2 or Z at 0, 7.5, 15, 30, 60 or 120 nM in the same fresh medium for 24 h. Cell proliferation rate was quantified by using CellTiter 96t AQueous assay (Promega, Madison, WI, USA). Briefly, at the end of treatment, the medium in the wells were discarded and 250 ml of fresh medium with 50 ml of freshly combined MTS/PMS (the ratio of MTS : PMS is 20 : 1)) solution was added to each well. Then, the plates were incubated for 1.5 h and the color density was checked every 30 min. Finally, 100 ml of culture medium from each well were transferred to one well of 96-well plates and optical density was read at 490 nm (OD 490 nm ) by an ELISA plate reader.
Statistical analysis
The results for DT assay and nonradioactive cell proliferation assay were presented as the mean7standard deviation (s.d.) for four replicate culture wells as one group. The results for colony efficiency assay were presented as the mean7s.d. for five individual fields as one well. Analysis was performed using Minitab statistical software for Windows (Minitab Inc., State College, PA, USA). Statistical differences were determined by using one-way ANOVA for independent groups. Pvalues of less than 0.05 were considered to be statistically significant.
